Revity (RVTY) Q2 2026: Diagnostics Up 11%, AI-Driven Backlog Sets Up Second-Half Growth
Revity’s Q2 highlighted a decisive pivot toward AI-enabled demand and diagnostics resilience, with a record instrument backlog positioning the company for accelerated second-half growth. The diagnostics segment outperformed, while life sciences showed early signs of AI-fueled recovery despite software headwinds. Management’s raised outlook reflects both end-market improvement and strategic reinvestment, as Revity leans into its differentiated platform amid sector transformation.
Summary
- AI-Driven Demand Surge: Instrument orders and backlog reached multi-year highs as AI adoption expands Revity’s customer base.
- Diagnostics Consistency: Segment resilience and broad-based growth underpinned margin and cash flow strength.
- Strategic Reinvestment: Raised guidance and reinvestment signal confidence in sustained end-market recovery.
Business Overview
Revity is a global provider of diagnostics, life sciences tools, and scientific software. The company generates revenue through two main segments: Diagnostics (reproductive health, immunodiagnostics, and newborn screening) and Life Sciences (instruments, reagents, and Signals software for scientific data management). Its business model centers on enabling preclinical R&D, clinical diagnostics, and data-driven discovery, with growing exposure to AI-enabled workflows and cloud-based software.
Performance Analysis
Q2 delivered 3% organic revenue growth on a pro forma basis, with total revenue of $711 million, exceeding internal expectations. Diagnostics led with 11% organic growth, driven by durable performance in reproductive health and immunodiagnostics, while life sciences declined 3% organically due to a planned software revenue trough. The company’s adjusted operating margin reached 29.3%, aided by $16 million in tariff refunds but also reflecting underlying operational improvement.
Free cash flow was robust at $184 million, representing 117% conversion of adjusted net income, and leverage improved following the retirement of a 500 million euro note. The diagnostics segment contributed $352 million in revenue, while life sciences generated $359 million, with both instruments and reagents showing positive momentum heading into Q3.
- Diagnostics Outperformance: Broad-based strength, especially in newborn screening and immunodiagnostics outside China, offset software headwinds in life sciences.
- Instrument Backlog Builds: High content screening orders, especially for the new Opera Phoenix Opt IQ, outpaced production, setting up a strong second-half revenue ramp.
- Software Volatility: Planned 20% YoY decline in Signals software masked underlying double-digit annualized portfolio value (APV) growth, with recovery expected in H2 as contract renewals accelerate.
Overall, Revity’s margin expansion and cash generation reflect both end-market improvement and disciplined cost management, positioning the company to capitalize on AI-driven demand and diagnostics stability.
Executive Commentary
"We are seeing a definitive and progressively larger increase in orders directly related to AI, reflecting demand from both traditional pharma and biotech customers, as well as emerging demand from non-traditional customers that have not historically purchased from us."
Prahlad Singh, President and Chief Executive Officer
"Our pro forma adjusted operating margins were still above the 27% assumption in our guidance. With what appears to be an improvement in end market conditions underway, we have chosen to reinvest about half of this one-time benefit back into our strategic initiatives, supply chain, and people to ensure we are well positioned to capitalize on the opportunities we see emerging."
Max Krakowiak, Senior Vice President and Chief Financial Officer
Strategic Positioning
1. AI-Enabled Demand and New Customer Segments
AI-driven discovery is reshaping Revity’s addressable market, with “lab in the loop” workflows driving demand for high content screening instruments and reagents. Notably, non-traditional buyers, including AI drug discovery startups and nonprofits, are now placing significant orders, expanding Revity’s customer base beyond legacy pharma and biotech.
2. Diagnostics Franchise as a Margin Anchor
Diagnostics delivered 11% organic growth, led by reproductive health (mid-teens growth in H1) and immunodiagnostics (high single digits outside China). The segment’s durability, even in a declining birth rate environment, provides a stable margin and cash flow foundation, allowing Revity to weather volatility in life sciences and reinvest strategically.
3. Signals Software Platform and Ecosystem Expansion
The Signals software business saw planned revenue contraction due to contract timing, but underlying APV grew double digits. New launches—SignalsAI, the Anthropic MCP connector, and the Signals for Startups program—are designed to embed AI and workflow automation deeper into the platform, increase stickiness, and unlock consumption-based revenue streams.
4. Portfolio Rationalization and Capital Discipline
The definitive agreement to divest the China immunodiagnostics business reflects strategic focus on higher-return markets, while the integration of ACD Labs enhances software capability. Retirement of euro-denominated debt and fixed-rate long-term debt structure demonstrate prudent balance sheet management, supporting future investment capacity.
5. Operational Efficiency and Reinvestment
Operational initiatives and cost actions are progressing, with incremental reinvestment of tariff refund benefits into supply chain, capacity expansion, and talent, aiming to ensure Revity can meet rising demand and accelerate innovation. Management expects these investments to drive further margin leverage and growth into 2027.
Key Considerations
Revity’s Q2 marks a turning point, as AI-driven workflows and diagnostics resilience converge to create a differentiated platform with expanding margin and growth potential.
Key Considerations:
- AI Infrastructure Build-Out: High content screening demand signals a secular shift, with initial instrument sales expected to drive future reagent pull-through as AI-generated hypotheses require lab validation.
- Software Revenue Recovery: Signals platform organic revenue is set to rebound in H2 as contract renewals and new product launches (SignalsAI, Labgistics) contribute to growth and retention.
- Diagnostics Durability: Newborn screening and reproductive health continue to outperform despite macro headwinds, providing a recurring revenue base and cash flow stability.
- Strategic Capital Allocation: Tariff refund windfall is being split between immediate margin benefit and reinvestment in capacity, innovation, and talent to sustain long-term competitive advantage.
- Portfolio Focus: China immunodiagnostics divestiture and ACD Labs integration sharpen Revity’s focus on high-return, innovation-driven segments.
Risks
Key risks include: slower-than-expected AI adoption in life sciences, potential delays in instrument delivery or reagent pull-through, and execution risk around software contract renewals. Diagnostics growth could moderate if birth rates decline further or if competitive dynamics intensify. Additionally, the China immunodiagnostics divestiture, while strategic, could introduce short-term regional volatility until completed in 2027.
Forward Outlook
For Q3 2026, Revity guided to:
- Organic revenue growth of 4% to 6%
- Revenue of $685 to $700 million
- Pro forma adjusted operating margins of approximately 29%
- Adjusted EPS to represent roughly 24% of full-year outlook
For full-year 2026, management raised guidance:
- Organic revenue growth of 4% to 5% (up from 3% to 4%)
- Adjusted operating margin of 28.7%
- Adjusted EPS of $5.30 to $5.40 (up $0.10 from prior guidance)
Management highlighted:
- H2 software growth recovery as contract renewals and new launches materialize
- Diagnostics growth to remain high single digits, with life sciences improving to low single digits for the year
Takeaways
Revity’s Q2 results and guidance raise reflect a business at the inflection of AI-driven demand and diagnostics resilience.
- AI Momentum Building: Instrument backlog and order acceleration suggest Revity is capturing early-stage AI infrastructure build-out, setting up multi-year reagent and software pull-through.
- Diagnostics as Growth Engine: Consistent outperformance in reproductive health and immunodiagnostics anchors margin and cash flow, supporting reinvestment and innovation.
- Watch for H2 Execution: Key areas to monitor include software revenue recovery, reagent acceleration, and the pace of AI-related order conversion into revenue.
Conclusion
Revity’s Q2 demonstrated the company’s ability to capitalize on emerging AI-driven demand while maintaining diagnostics leadership and operational discipline. With a record instrument backlog, robust cash flow, and raised guidance, the business is well positioned for the second half and beyond, though execution on software and reagent pull-through will be critical to sustaining momentum.
Industry Read-Through
Revity’s results underscore a broader inflection in life sciences as AI adoption transitions from infrastructure build-out to real-world application, driving new demand for high content screening and data management tools. The accelerating “lab in the loop” workflow trend signals opportunity for peers with instrument, reagent, and software exposure, but also raises the bar for integrated platform capability. Diagnostics resilience, particularly in reproductive health and newborn screening, remains a key margin anchor industry-wide. Portfolio rationalization and strategic reinvestment, as seen with Revity’s China divestiture and software expansion, are likely to become more prevalent as companies seek to focus on high-return, innovation-driven businesses in a rapidly evolving landscape.